Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Adjuvant ipilimumab bij stadium III-melanoom
jan 2017 | Dermato-oncologie, Immuuntherapie